CRISPR Therapeutics (CRSP) Stock Drops 10% — Cathie Wood’s Ark Buys the Dip

TLDR

• ARK Invest bought ~281,000 CRSP shares worth ~$14.82M after the stock fell 10%
• The drop was triggered by CRISPR Therapeutics announcing a $350M private offering
• CRSP is ARK’s second-largest holding across all ETFs, with ~$500M total exposure
• ARK trimmed positions in 10x Genomics (TXG) and Teradyne (TER) as part of rebalancing
• Seeking Alpha Quant and Wall Street analysts both rate CRSP a Buy

CRISPR Therapeutics (CRSP) fell around 10% after the company announced a $350M private offering. Cathie Wood’s ARK Invest moved quickly, buying the dip.

CRISPR Therapeutics AG, CRSP

ARK purchased approximately 281,000 CRSP shares across its ETFs, totaling about $14.82M. The trades were disclosed in ARK’s daily trading report on March 11, 2026.

This wasn’t a one-off move. In Q4 2025, Wood had already increased ARK’s CRSP position by 7.5%, adding around 735,000 shares. The latest buy continues that trend.

CRSP is now ARK’s second-largest holding across all its combined ETFs, carrying a 4.49% portfolio weight and roughly $500M in total exposure. That’s a big bet on a stock that doesn’t yet generate revenue.

The Offering That Spooked the Market

The 10% drop came after CRISPR Therapeutics announced a $350M private placement. Offerings like this dilute existing investors, which tends to push the stock lower in the short term.

The capital raise wasn’t out of nowhere. CRISPR Therapeutics has no revenue and negative operating margins, so raising cash to fund its pipeline is part of the business model at this stage.

The company does have a strong balance sheet to lean on — a current ratio of 13.32 and a debt-to-equity ratio of 0.11 point to solid liquidity and very low debt.

That financial cushion is likely part of why ARK felt comfortable stepping in after the drop.

What CRSP Is Working On

CRISPR Therapeutics’ first approved product, Casgevy, was developed with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia.

Beyond Casgevy, the company is working on programs in immuno-oncology, cardiovascular disease, and stem cell-derived therapies for Type 1 diabetes.

The company’s market cap sits at approximately $5.07 billion as of the latest reports.

Insider activity has been one-sided lately — five insider selling transactions over the past three months totaling 163,751 shares, with no insider buying.

Rebalancing Elsewhere

As ARK added to CRSP, it trimmed in other areas. ARK sold 78,412 shares of 10x Genomics (TXG) for about $1.60M and offloaded 21,505 shares of Teradyne (TER) for $6.47M.

Those moves appear to be routine rebalancing across ARK’s actively managed ETF lineup rather than a specific negative view on those names.

On the ratings front, CRSP holds a Buy rating from both Seeking Alpha’s Quant system and Wall Street analysts. The Quant model gives its highest marks to growth and momentum.

One Seeking Alpha contributor pointed to Casgevy’s commercial launch and the company’s cash reserves as key positives, while flagging the risks that come with a pre-revenue biotech.

GF Value from GuruFocus currently pegs CRSP as significantly overvalued at a GF Value of $16.13, a contrast to the bullish analyst consensus.

CRSP closed down roughly 10.17% on the day the offering was announced.

The post CRISPR Therapeutics (CRSP) Stock Drops 10% — Cathie Wood’s Ark Buys the Dip appeared first on CoinCentral.